Fibrocell Science Extends Patent Protection for LAVIV® (azficel-T) Through 2031

Fibrocell Science, Inc. FCSC, creator of the first FDA-approved autologous cellular product, LAVIV® (azficel-T) for aesthetics, announced today that the United States Patent and Trademark Office (USPTO) has awarded a patent to the Company which covers azficel-T fibroblast suspension, extending the patent exclusivity in the United States until 2031. “The granting of this patent is a significant milestone for Fibrocell, further validating our autologous fibroblast technology,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell Science. “We are focused on unlocking the potential of the autologous fibroblast and look forward to developing our cellular technology for a wide variety of applications.” About Fibrocell Science, Inc. Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com. About LAVIV® (azficel-T) LAVIV is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established. The efficacy of LAVIV beyond six months has not been established. Important Safety Information about LAVIV® (azficel-T) LAVIV (azficel-T) is an autologous cellular product for intradermal injection only. LAVIV is contraindicated for allogeneic use, in patients with allergy to gentamicin, amphotericin, dimethyl sulfoxide (DMSO) or material of bovine origin and in patients with active infection in the facial area. The following reactions have been reported following treatment with LAVIV: hypersensitivity reactions, bleeding and bruising at the treatment site, vasculitis, herpes labialis, basal cell cancer; keloid and hypertrophic scarring may occur following post-auricular skin biopsies or LAVIV injections. Additional warnings and precautions to be considered include the use of LAVIV in patients with genetic disorders or formation of normal collagen matrices and in immunosuppressed patients, or those patients undergoing chemotherapy for malignancies or receive immunomodulatory therapies for autoimmune diseases. The most common adverse reactions, occurring in ≥1% of patients who receive LAVIV, were injection-site redness, bruising, swelling, pain, hemorrhage, edema, nodules, papules, irritation, dermatitis and pruritus. For more information about LAVIV, please see the accompanying full Prescribing Information or visit www.mylaviv.com.